ES2656988T3 - Biomarcador para el cáncer de mama - Google Patents
Biomarcador para el cáncer de mama Download PDFInfo
- Publication number
- ES2656988T3 ES2656988T3 ES12770851.9T ES12770851T ES2656988T3 ES 2656988 T3 ES2656988 T3 ES 2656988T3 ES 12770851 T ES12770851 T ES 12770851T ES 2656988 T3 ES2656988 T3 ES 2656988T3
- Authority
- ES
- Spain
- Prior art keywords
- lat1
- expression
- her2
- kit
- staining
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57407—Specifically defined cancers
- G01N33/57415—Specifically defined cancers of breast
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Biomedical Technology (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Food Science & Technology (AREA)
- Physics & Mathematics (AREA)
- Pathology (AREA)
- Organic Chemistry (AREA)
- General Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Cell Biology (AREA)
- Oncology (AREA)
- Hospice & Palliative Care (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2011091378 | 2011-04-15 | ||
JP2011091378 | 2011-04-15 | ||
PCT/JP2012/060114 WO2012141285A1 (fr) | 2011-04-15 | 2012-04-13 | Biomarqueur pour le cancer du sein |
Publications (1)
Publication Number | Publication Date |
---|---|
ES2656988T3 true ES2656988T3 (es) | 2018-03-01 |
Family
ID=47009444
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ES12770851.9T Active ES2656988T3 (es) | 2011-04-15 | 2012-04-13 | Biomarcador para el cáncer de mama |
Country Status (7)
Country | Link |
---|---|
US (1) | US9618512B2 (fr) |
EP (1) | EP2698634B1 (fr) |
JP (1) | JP6075881B2 (fr) |
KR (1) | KR101976219B1 (fr) |
CN (1) | CN103547923B (fr) |
ES (1) | ES2656988T3 (fr) |
WO (1) | WO2012141285A1 (fr) |
Families Citing this family (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103808937B (zh) * | 2014-03-13 | 2015-11-18 | 广州恒泰生物科技有限公司 | 用于乳腺癌早中期快速诊断试剂盒及其检测方法 |
CA2939241A1 (fr) * | 2014-04-08 | 2015-10-15 | Arno Therapeutics, Inc. | Systemes et procedes d'identification de sous-types de recepteurs de la progesterone |
KR20170084086A (ko) | 2014-11-17 | 2017-07-19 | 아르노 테라퓨틱스 인코포레이티드 | 오나프리스톤 연장-방출 조성물 및 방법 |
JPWO2016103761A1 (ja) * | 2014-12-22 | 2017-11-02 | ジェイファーマ株式会社 | 癌の血中バイオマーカー |
BR112018005999A2 (pt) | 2015-09-25 | 2019-01-08 | Context Biopharma Inc | métodos para a produção de intermediários de onapristona |
JP6599710B2 (ja) * | 2015-09-29 | 2019-10-30 | 公益財団法人ヒューマンサイエンス振興財団 | カクテル抗体 |
CN105238763A (zh) * | 2015-10-26 | 2016-01-13 | 无锡傲锐东源生物科技有限公司 | 抗pr蛋白单克隆抗体杂交瘤细胞及其产生的抗pr单克隆抗体和应用 |
KR20180113988A (ko) | 2015-12-15 | 2018-10-17 | 컨텍스트 바이오파마 인코포레이티드 | 비정질 오나프리스톤 조성물 및 그 제조방법 |
US20180148471A1 (en) | 2016-11-30 | 2018-05-31 | Arno Therapeutics, Inc. | Methods for onapristone synthesis dehydration and deprotection |
CN107200779B (zh) * | 2017-07-03 | 2020-04-03 | 中国农业大学 | 稳定过表达LAT3的β细胞株的制备方法及其应用 |
CN110215448B (zh) * | 2018-03-02 | 2022-09-20 | 中国医学科学院基础医学研究所 | 一种含有转运蛋白抑制剂的药物、药物组合物及用途 |
JP2019158777A (ja) * | 2018-03-16 | 2019-09-19 | 東ソー株式会社 | 腫瘍マーカーならびに腫瘍細胞を夾雑細胞と区別して回収および検出する方法 |
IT201800004137A1 (it) * | 2018-03-30 | 2019-09-30 | Domenico Marina Di | Metodo di screening in vitro per diagnosi precoce dei tumori del cavo orale e relativo kit, basato in particolare su saggio elisa |
CN110376036A (zh) * | 2019-07-30 | 2019-10-25 | 河南赛诺特生物技术有限公司 | 一种肿瘤细胞系免疫组化对照品的制备方法及肿瘤细胞系免疫组化对照品 |
KR20220141216A (ko) | 2021-04-12 | 2022-10-19 | 연세대학교 산학협력단 | 유방암 진단을 위한 신규 바이오마커 |
CN116333115B (zh) * | 2023-05-12 | 2023-07-28 | 北京纳百生物科技有限公司 | 一种抗孕酮的单克隆抗体、试剂盒及应用 |
Family Cites Families (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5698410A (en) | 1995-06-07 | 1997-12-16 | Mount Sinai School Of Medicine Of The City University Of New York | Highly sensitive immunocytochemical method for diagnosis of malignant effusions |
JP4689781B2 (ja) | 1998-09-03 | 2011-05-25 | 独立行政法人科学技術振興機構 | アミノ酸輸送蛋白及びその遺伝子 |
JP4326626B2 (ja) | 1999-06-04 | 2009-09-09 | 独立行政法人科学技術振興機構 | 広い基質選択性を有する中性アミノ酸トランスポーター及びその遺伝子 |
JP4592131B2 (ja) | 1999-08-05 | 2010-12-01 | ジェイファーマ株式会社 | シスチン、塩基性アミノ酸及び中性アミノ酸を基質とするトランスポーター及びその遺伝子 |
JP2001228146A (ja) | 1999-12-07 | 2001-08-24 | Takeda Chem Ind Ltd | 疾患関連遺伝子の用途 |
JP2001211886A (ja) | 2000-02-07 | 2001-08-07 | Japan Science & Technology Corp | L−体及びd−体アミノ酸を輸送するナトリウム非依存性小型中性アミノ酸トランスポーター及びその遺伝子 |
JP3507884B2 (ja) | 2000-03-07 | 2004-03-15 | 新潟大学長 | 遺伝子発現を指標とする統合失調症の客観的診断法 |
TWI390034B (zh) * | 2006-04-06 | 2013-03-21 | Kyowa Hakko Kirin Co Ltd | Novel anti-CD98 antibody |
US20100112596A1 (en) * | 2007-02-06 | 2010-05-06 | J-Pharma Co., Ltd. | Kit for deciding degree of malignancy in prostate cancer and method of using the same |
CN101932938B (zh) * | 2007-11-30 | 2014-08-27 | 克雷特诊疗服务公司 | 作为标记物用于化学疗法的tle3 |
JP2011024537A (ja) * | 2009-07-29 | 2011-02-10 | Kinki Univ | トランスポーターに対する抗体およびその用途 |
-
2012
- 2012-04-13 WO PCT/JP2012/060114 patent/WO2012141285A1/fr active Application Filing
- 2012-04-13 EP EP12770851.9A patent/EP2698634B1/fr active Active
- 2012-04-13 US US14/111,401 patent/US9618512B2/en active Active
- 2012-04-13 KR KR1020137029685A patent/KR101976219B1/ko active IP Right Grant
- 2012-04-13 JP JP2013509975A patent/JP6075881B2/ja active Active
- 2012-04-13 CN CN201280023071.2A patent/CN103547923B/zh active Active
- 2012-04-13 ES ES12770851.9T patent/ES2656988T3/es active Active
Also Published As
Publication number | Publication date |
---|---|
JPWO2012141285A1 (ja) | 2014-07-28 |
KR20140019833A (ko) | 2014-02-17 |
US20140106377A1 (en) | 2014-04-17 |
EP2698634B1 (fr) | 2017-11-08 |
EP2698634A4 (fr) | 2014-11-26 |
CN103547923B (zh) | 2015-08-12 |
CN103547923A (zh) | 2014-01-29 |
KR101976219B1 (ko) | 2019-05-07 |
US9618512B2 (en) | 2017-04-11 |
EP2698634A1 (fr) | 2014-02-19 |
WO2012141285A1 (fr) | 2012-10-18 |
JP6075881B2 (ja) | 2017-02-08 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ES2656988T3 (es) | Biomarcador para el cáncer de mama | |
Pellat et al. | Clinical and biomarker evaluations of sunitinib in patients with grade 3 digestive neuroendocrine neoplasms | |
Kurokawa et al. | Expression of GLUT‐1 glucose transfer, cellular proliferation activity and grade of tumor correlate with [F‐18]‐fluorodeoxyglucose uptake by positron emission tomography in epithelial tumors of the ovary | |
Matei et al. | Neuroendocrine differentiation in castration-resistant prostate cancer: a systematic diagnostic attempt | |
Cheng et al. | Diagnostic value of different phenotype circulating tumor cells in hepatocellular carcinoma | |
KIRSTEN et al. | Metastatic Adeno or Undifferentiated Carcinoma from an Unknown Primary Site Natural History and Guidelines for Identification of Treatable Subsets | |
JP5616892B2 (ja) | 前立腺癌バイオマーカー | |
ES2700367T3 (es) | Nuevos biomarcadores para el cáncer de mama metastásico | |
JP2015513083A (ja) | Psma上昇により致死性前立腺癌が同定される | |
Hoskovec et al. | Peritoneal lavage examination as a prognostic tool in cases of gastric cancer | |
Tobi et al. | Prospective markers for early diagnosis and prognosis of sporadic pancreatic ductal adenocarcinoma | |
Zhang et al. | Prognostic and predictive role of COX-2, XRCC1 and RASSF1 expression in patients with esophageal squamous cell carcinoma receiving radiotherapy | |
Zhang et al. | Clinical strategies for differentiating IgG4-related cholecystitis from gallbladder carcinoma to avoid unnecessary surgical resection | |
ES2776733T3 (es) | Kit que comprende un anticuerpo que se une específicamente a la proteína del factor B del complemento y un anticuerpo que se une específicamente a la proteína del antígeno carbohidrato 19-9 para el diagnóstico del cáncer pancreático | |
Kutomi et al. | Clinicopathological characteristics of basal type breast cancer in triple-negative breast cancer | |
Arhan et al. | DR-70 as a novel diagnostic biomarker for gastric cancer | |
CN109116023B (zh) | 一种肺癌标志物抗-mmp12自身抗体及其应用 | |
Madani et al. | Survey of Her2-neu expression and its correlation with histology of gastric carcinoma and gastroesophageal junction adenocarcinoma | |
JP2011209101A (ja) | CapGをマーカーとする悪性腫瘍の予後予測検査方法 | |
Cambruzzi et al. | The relationship between serum levels of CA 125 and the degree of differentiation in ovarian neoplasms | |
Ebeed et al. | Diagnostic and prognostic value of circulating tumor cells in female breast cancer patients | |
Tanei et al. | High HER2 intratumoral heterogeneity is a predictive factor for poor prognosis in Early-stage and Locally Advanced HER2-positive Breast Cancer | |
Al Saihati | Elevated CEA and CA15-3 Serum Levels in Different Molecular Subtypes of Breast Cancer Have Prognostic Significance. | |
Lee et al. | The predictive value of serum HER2/neu for response to anthracycline-based and trastuzumab-based neoadjuvant chemotherapy | |
Chang et al. | Prognostic significance of p27, Ki-67, and topoisomerase IIα expression in clinically nonfunctioning pancreatic endocrine tumors |